The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brooks, B.
Right arrow Articles by Coleman, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brooks, B.
Right arrow Articles by Coleman, J. W.
The Journal of Immunology, 2000, 164: 573-579.
Copyright © 2000 by The American Association of Immunologists

Presentation of IFN-{gamma} to Nitric Oxide-Producing Cells: A Novel Function for Mast Cells1

Bernadette Brooks*, David M. Briggs*, Nigel C. Eastmond*, David G. Fernig{dagger} and John W. Coleman2,*

* Department of Pharmacology and Therapeutics, and {dagger} School of Biological Sciences, University of Liverpool, Liverpool, United Kingdom


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
We report that mast cells can bind and present IFN-{gamma} in a functionally active form to macrophages. Flow-cytometric analysis revealed that biotinylated IFN-{gamma} bound equally well to purified peritoneal mast cells from both IFN-{gamma}R knockout and wild-type mice, indicating a non-IFN-{gamma}R binding site. Purified peritoneal mast cells, loaded with IFN-{gamma} for 30 min and washed, were able to induce NO synthesis by peritoneal macrophages. This response required cell contact and expression of IFN-{gamma}R on the responding macrophages, but not the mast cells. Human HMC-1 mast cells were also able to present IFN-{gamma} to mouse macrophages. Enzyme treatment of mouse mast cells revealed that binding of IFN-{gamma} was predominantly to chondroitin sulfate B (dermatan sulfate). Binding of IFN-{gamma} to dermatan sulfate was confirmed by inhibition ELISA. This study demonstrates for the first time that mast cells can present IFN-{gamma} to other cells via glycosaminoglycans. Mast cells may act as a reservoir of surface-stored functionally active cytokines.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
The T cell- and NK cell-derived cytokine IFN-{gamma} exerts a wide range of immune-regulatory and inflammatory activities. These include promotion of Th1 cell differentiation, up-regulation of MHC molecules, activation of macrophages, and stimulation of expression of the inducible form (type II) of NO synthase (1, 2). IFN-{gamma} may also influence immediate hypersensitivity reactions and other processes dependent on mast cells. For example, it inhibits IgE-mediated mast cell degranulation (3, 4, 5, 6), TNF-{alpha}-mediated cytotoxicity (7), and clonal proliferation of rodent connective tissue type mast cells (8). In cell culture systems employing density-gradient fractionated mast cells, it is uncertain whether the effects of IFN-{gamma} are direct or occur via the small proportion of contaminating nonmast cells. In the case of IgE-mediated degranulation of mouse and rat peritoneal mast cells, the inhibitory action of the cytokine is certainly indirect and the active intermediate has been identified as NO (9, 10). IL-4 enhances degranulation of mouse and rat peritoneal mast cells (10, 11), and, at least in the rat, this is due to inhibition of NO synthesis by accessory cells (10).

Although IFN-{gamma} does not cause purified rodent peritoneal mast cells to produce NO and does not inhibit degranulation by a direct action, it is not clear whether this is due to lack of mast cell expression of the IFN-{gamma} receptor (IFN-{gamma}R). The IFN-{gamma}R is expressed on all nucleated cells studied to date. It is ligand and species specific, composed of three subunits of which the {alpha}-chain has high affinity for IFN-{gamma}, and is linked to the Jak-STAT signal transduction pathway (1, 2).

Unexpectedly, we found that biotinylated IFN-{gamma} bound equally well to IFN-{gamma}R knockout (KO)3 (3) and wild-type (WT) purified mast cells, indicating a unique binding site. One possible candidate is cell surface proteoglycans. In common with other cytokines and growth factors, human IFN-{gamma} has been shown to bind to proteoglycans of the extracellular matrix, and more specifically to the glycosaminoglycans (GAGs) heparin, heparan sulfate, and chondroitin sulfate (12, 13, 14, 15, 16). The binding interaction between human IFN-{gamma} and heparan sulfate has been well characterized: it involves two groups of carboxyl-terminal basic amino acids on the cytokine and two sulfated domains of heparan sulfate, such that the two domains of the GAG directly bind the two carboxyl-terminals of an IFN-{gamma} dimer (13, 17, 18, 19). Although soluble GAGs can inhibit IFN-{gamma} activity, IFN-{gamma} bound to immobilized GAGs is biologically active (12, 14, 15, 16, 20, 21). In the present study, we examined two important questions pertaining to mast cell-bound IFN-{gamma}. First, is the cell-bound cytokine functionally active? Second, what is the identity of the binding site? To test for functional activity, we used mouse peritoneal macrophages that respond to IFN-{gamma} by induced expression of type II NO synthase and high level NO synthesis (22, 23). As a control, to examine whether the IFN-{gamma} effect was direct, we used IFN-{gamma}R KO responder cells. The results showed that mast cell-bound IFN-{gamma} did induce NO release by macrophages, and the effect was dependent on IFN-{gamma}R expression by the responder cells. Further studies, using GAG-selective enzymes, indicated that chondroitin sulfate B (dermatan sulfate) is the IFN-{gamma} binding site on mast cells. These studies show that mast cells have the capacity to bind IFN-{gamma} via GAGs and to present it in a functionally active form to NO-producing cells. This represents a novel cytokine-presenting function for mast cells. Since mast cells are resident in many tissues and are also recruited to inflammatory sites (24, 25), they may provide a site for cytokine sequestration and for cytokine transport into tissues. The mast cell may serve as a useful paradigm for further studies of cytokine sequestration and presentation by inflammatory cells.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Mice

IFN-{gamma}R KO and IFN-{gamma}R WT 129 Sv/Ev mice were bred from stock obtained from B & K Universal (Hull, U.K.) and were used with kind permission of Dr. S. Huang (Institute of Molecular Biology, Zürich, Switzerland) (26). Phenotype was checked by the capacity of peritoneal cells to respond to IFN-{gamma} by generating nitrite.

Cells

Cells were obtained by peritoneal lavage of mice with HBSS (Life Technologies, Paisley, Scotland) and sedimented by centrifugation at 260 x g for 5 min. The cell pellets were pooled (typically from four to six mice), resuspended in 7.5 ml of 72.5% isotonic Percoll (Sigma, Poole, U.K.), and overlaid with 2 ml of complete DMEM (Life Technologies) containing 5% FCS (Life Technologies), 4 mM L-glutamine, and 50 µg/ml gentamicin (cDMEM). The gradient was centrifuged at 400 x g for 15 min. Mast cells were recovered from the pellet and mast cell-depleted peritoneal cells from the Percoll-DMEM interface. All cells were suspended in cDMEM. The mast cell fraction was >98% pure and contained <2% macrophages, whereas the interface cells comprised <2% mast cells and >98% macrophages, as determined by staining in 0.02% toluidine blue and by Giemsa staining of cytospin preparations. The cells were cultured in cDMEM in conical sterile plastic tubes at 37°C with 5% CO2 in air, usually for 24 h.

Human mast cells of the HMC-1 cell line (27) were grown in IMDM (Life Technologies) containing 10% FCS and subcultured weekly at 1:10.

Mast cell challenge and serotonin release assay

[3H]Serotonin (5-[1,2-N-3H]hydroxytryptamine creatinine sulfate (sp. act., 27 Ci/mmol; DuPont-NEN, Dreiech, Germany) was added (1 µCi/ml) for the final 2 h of peritoneal mast cell culture. At the termination of culture, the mast cells were washed three times with cDMEM and resuspended (104/ml) in challenge medium (cDMEM buffered to pH 7 with HEPES). The cells (100 µl) were added in duplicate to 100 µl of challenge medium (background control), rat monoclonal anti-mouse IgE (200 ng/ml, kindly provided by Dr. F. D. Finkelman, Uniformed Services University of the Health Sciences, Bethesda, MD), or 0.05% Triton X-100 to lyse the cells. The cells were incubated for 30 min, after which they were centrifuged at 350 x g for 2 min and 100 µl of supernatant medium was removed for scintillation counting. Percentage of specific release of [3H]serotonin from mast cells was measured as (a - b)/c, in which a = cpm for anti-IgE-treated cells, b = mean cpm for control cells, and c = cpm for lysed cells.

Fluorescence flow cytometry

Murine rIFN-{gamma} (R&D Systems, Oxon, U.K.) was biotinylated by incubating 25 µg of protein in 0.25 ml PBS with 3 µl of biotin-X-N-hydroxysuccinimide ester (10 mg/ml in DMSO; Calbiochem, Nottingham, U.K.) for 4 h at 37°C. The reaction was quenched with equimolar glycine, and the solution was dialyzed extensively against PBS. This biotinylated IFN-{gamma} retained biological activity. The biotinylated IFN-{gamma} was added (1:10) to 50 µl of purified mouse peritoneal mast cells (2 x 105/ml in PBS containing 0.1% FCS) for 30 min on ice. The cells were washed twice in ice-cold PBS and resuspended in 50 µl of PBS containing streptavidin-PE (1:50) for 30 min on ice, washed twice, and resuspended in 0.5 ml of ice-cold PBS. As negative control, the biotinylated IFN-{gamma} was omitted. The cells were analyzed by flow cytometry (FACScan; Becton Dickinson, Mount View, CA).

Nitrite assay

NO synthesis was measured as accumulation of nitrite (a stable product of NO) in the culture medium by the Griess reaction (28). Samples and NaNO2 standards (150 µl) were added in duplicate to 96-well microtiter plates. Then, 50 µl of Griess reagent (1% sulfanilamide and 0.1% N-(1-napthyl) ethylenediamine dihydrochloride in 45% acetic acid) was added to each well, and the samples were incubated for 10 min at room temperature. Absorbances at 570 nm were read on an automatic plate reader (MR 600; Dynatech Instruments, Torrance, CA). The values of nitrite concentration in the culture samples were obtained from the standard curve.

Inhibition ELISA for GAG binding to IFN-{gamma}

An ELISA for measuring GAG binding to IFN-{gamma} was adapted from a previous study (29). Ninety-six-well microtiter plates (Falcon Probind ELISA plates; Fred Baker, Runcorn, U.K.) were coated with carrier-free murine rIFN-{gamma} (2 µg/ml; Peprotech, London, U.K.) in carbonate buffer, pH 9.6, for 18 h at 4°C. The plates were washed three times with PBS containing 0.05% Tween 20 (PBS-T; Sigma, Poole, Dorset, U.K.). GAGs were then added in triplicate to the top row of wells and serially diluted down the plate in PBS-T. The plates were incubated for at least 1 h at room temperature, and then heparin-BSA-biotin (Sigma) was added at a final concentration of 2 µg/ml for at least 1 h. Positive controls were wells with no GAG added, and negative controls were wells with BSA-biotin (Sigma) in place of heparin-BSA-biotin. The plates were washed three times in PBS-T, and extravidin-HRP (1:2000; Sigma) was added for 1 h. Plates were washed again before addition of 50 µl of o-phenylenediamine substrate solution (Sigma). The reaction was terminated by addition of 20 µl of 3 M HCl, and absorbance was read at 490 nm, reference 630 nm. GAGs used were: heparan sulfate (bovine trachea; Sigma H7640); chondroitin sulfate A (bovine trachea; Sigma C8529); chondroitin sulfate B (porcine intestinal mucosa; Sigma C3788); chondroitin sulfate C (shark cartilage; Sigma C4383); and hyaluronic acid (bovine trachea; Sigma H0902).

Statistics

Data are presented as the mean ± SEM of several experiments or as representative experiments, and statistical analyses are by Student’s t test or Mann-Whitney U test, as appropriate.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
The cellular target for IFN-{gamma} in the inhibition of mast cell degranulation and induction of NO synthesis by peritoneal cells

It is known that IFN-{gamma} induces NO synthesis and inhibits Ag-induced mast cell degranulation in mouse peritoneal cell populations. To examine definitively the cellular target for IFN-{gamma} in mast cell inhibition, we added the cytokine for 24 h to cocultures of IFN-{gamma}R KO mast cells with IFN-{gamma}R WT accessory cells (gradient interface cells, >98% macrophages), or to cocultures of IFN-{gamma}R WT mast cells with IFN-{gamma}R KO accessory cells. The ratio of mast cells to accessory cells in these experiments was 1:10. Only in cultures containing IFN-{gamma}R WT accessory cells did IFN-{gamma} inhibit anti-IgE-induced mast cell serotonin release (Fig. 1GoA) and induce nitrite production (Fig. 1GoB). IFN-{gamma} was without effect on either parameter in cultures containing IFN-{gamma}R WT mast cells plus IFN-{gamma}R KO accessory cells (Fig. 1Go). Thus, macrophages, not mast cells, are the target for IFN-{gamma}-induced NO synthesis in peritoneal cell populations and are responsible indirectly for the IFN-{gamma}-dependent inhibition of mast cell degranulation.



View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 1. Effects of IFN-{gamma} on serotonin release and nitrite production in mixed cell cultures. Cocultures of IFN-{gamma}R KO mast cells plus IFN-{gamma}R WT accessory cells (gradient interface cells, >98% macrophages), or of IFN-{gamma}R WT mast cells plus IFN-{gamma}R KO accessory cells were incubated for 24 h with (hatched bars) or without (open bars) 10 ng/ml of IFN-{gamma}. Mast cells were at 105/ml and accessory cells at 106/ml. At the termination of culture, the cells were washed and challenged with anti-IgE for measurement of mast cell serotonin release (A) and the supernatant medium removed for measurement of nitrite (B). Results are means ± SEM for four separate experiments, each performed in quadruplicate. *, p < 0.05 by paired Student’s t test, for comparison of cells cultured with IFN-{gamma} to control (Con) cells.

 
Binding of IFN-{gamma} to mast cells

Although IFN-{gamma} did not act directly on mast cells to induce inhibitory levels of NO (Fig. 1Go) (9), we nevertheless examined whether the cytokine bound to these cells. Purified IFN-{gamma}R WT or KO mast cells were incubated with biotinylated IFN-{gamma} for 30 min at 37°C and analyzed by flow cytometry. The cytokine bound to both mast cell phenotypes (Fig. 2Go). This shows that IFN-{gamma} interacts with a site on mast cells, which is distinct from the IFN-{gamma}R. In two of three experiments, there was greater binding of IFN-{gamma} to WT compared with KO mast cells. This probably reflects additional binding to the IFN-{gamma}R on the WT cells.



View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 2. Flow-cytometric analysis of IFN-{gamma} binding to IFN-{gamma}R WT and IFN-{gamma}R KO purified mast cells. Continuous lines show positive staining with biotinylated IFN-{gamma}; dotted lines show negative control staining on omission of the IFN-{gamma}. Results are from a single experiment representative of three.

 
Mast cell presentation of IFN-{gamma}

We examined whether mast cell-bound IFN-{gamma} retained functional activity in relation to activation of NO synthesis by mouse peritoneal macrophages. Purified IFN-{gamma}R WT mouse mast cells or HMC-1 human mast cells were incubated with a range of concentrations of murine IFN-{gamma} for 30 min at 37°C. The mast cells were washed three times and then cocultured with mouse peritoneal cells (responder cells, >98% macrophages) for 24 h. Free IFN-{gamma} was added to responder cells alone as a positive control. Both types of mast cells induced nitrite production by the responder cells to a degree dependent on the loading concentration of IFN-{gamma} (Fig. 3Go). Mast cells that had not been treated with IFN-{gamma} failed to induce nitrite production; loading with IFN-{gamma} concentrations of 1 ng/ml or above induced a significant response (Fig. 3Go). Free IFN-{gamma} at concentrations of 0.01 ng/ml and above induced nitrite production (Fig. 3Go).



View larger version (13K):
[in this window]
[in a new window]
  		FIGURE 3. Nitrite production by peritoneal macrophages stimulated with free and mast cell-bound murine IFN-{gamma}. Peritoneal cells (106/ml) were stimulated with free IFN-{gamma} or mast cells (mouse peritoneal or human HMC-1) that had been preincubated for 30 min with IFN-{gamma} at the concentrations indicated and then washed extensively. The mast cell:macrophage ratio was 1:10. After 24 h, the supernatants were removed for nitrite determination. All data points were significantly different from control (no IFN-{gamma}) at concentrations above 0.01 ng/ml for free IFN-{gamma} and above 1 ng/ml for loading of presenting mast cells (p < 0.05 by paired Student’s t test).

 
Coculture experiments with mast cells and macrophages confirmed that IFN-{gamma} presentation does not require IFN-{gamma}R expression by mast cells, but is dependent upon IFN-{gamma}R expression by responding macrophages. IFN-{gamma}R WT or KO mast cells were incubated with IFN-{gamma} for 30 min, washed, and added to IFN-{gamma}R WT or KO responder cells. IFN-{gamma}-treated mast cells induced nitrite production only when the responder cells were IFN-{gamma}R WT, whereas the capacity to present IFN-{gamma} was independent of the mast cell phenotype (Fig. 4Go). In parallel experiments, we showed that macrophages could also present IFN-{gamma} to responder cells. Again, we found that nitrite production was dependent largely on the expression of the IFN-{gamma}R on the responding population, although low levels of nitrite were produced by IFN-{gamma}-pulsed WT macrophages (data not shown).



View larger version (14K):
[in this window]
[in a new window]
  		FIGURE 4. Requirements for IFN-{gamma}R expression on mast cells and responder cells. IFN-{gamma}R WT or IFN-{gamma}R KO mast cells were incubated with IFN-{gamma} (10 ng/ml) for 30 min, washed, and added to IFN-{gamma}R WT or IFN-{gamma}R KO responder cells for 24 h. Supernatants were removed for nitrite determination. *, p < 0.05 by paired Student’s t test, for comparison of KO with WT responder cells.

 
Mast cell presentation of IFN-{gamma} requires cell-cell contact

To examine whether mast cell presentation of IFN-{gamma} required cell contact, IFN-{gamma}-loaded mast cells (105 in 0.25 ml) were added either directly to responder cells (106 in 0.25 ml), or the two cell populations were separated by placing the mast cells inside a transwell (0.45 µm pore size; Corning Costar, High Wycombe, U.K.) that was inserted into the macrophage suspension in the base of a conical tube. The transwells allow transfer only of soluble molecules, not cells, through a semipermeable membrane. Fig. 5Go shows that physical separation of the two cell types abolished NO induction by the responder macrophages over 24 h of culture. Thus, the IFN-{gamma} effect is dependent on cell-cell contact. Moreover, it is unlikely that IFN-{gamma} shed from cells loaded with only 10 ng/ml and subsequently washed extensively would reach the concentrations required in solution to induce NO production (Fig. 3Go).



View larger version (13K):
[in this window]
[in a new window]
  		FIGURE 5. Presentation of IFN-{gamma} requires cell-cell contact. Purified mouse peritoneal mast cells were incubated with IFN-{gamma} (10 ng/ml) for 30 min, washed, and added (105 in 0.25 ml) either directly to responder cells (106 in 0.25 ml), or the two cell populations were separated by placing the mast cells inside a transwell inserted into the macrophage suspension. After 24 h, the supernatants were recovered for nitrite assay. Results are means ± SEM for four separate experiments, each performed in quadruplicate. *, p < 0.05 by Mann-Whitney U test for comparison of cells separated or not separated by the transwell membrane.

 
Identification of GAGs involved in mast cell presentation of IFN-{gamma}

Mast cell binding and presentation of IFN-{gamma} were independent of expression of IFN-{gamma}R and required cell-cell contact. Therefore, we speculated that presentation might be via GAGs. In the first series of experiments, purified mouse mast cells, or peritoneal macrophages prepared as gradient interface cells (both at 105/ml), were incubated with heparinase (1 U/ml; Sigma) or chondroitinase ABC (1 U/ml; Sigma) for 1 h at 37°C in cDMEM. After washing, they were loaded with IFN-{gamma} at 10 ng/ml for 30 min, washed again, then added (2 x 105/ml) to responder peritoneal cells (2 x 106/ml) for 24 h, in a final volume of 0.25 ml. Heparinase significantly inhibited the capacity of the macrophages (but not mast cells) to present IFN-{gamma} to the NO-producing cells. However, chondroitinase ABC inhibited the capacity of mast cells, but not macrophages, to present IFN-{gamma} (Fig. 6Go). In a second series, purified mast cells (105/ml) were incubated with chondroitinase ABC (1 U/ml), chondroitinase AC (1 U/ml; Sigma), or chondroitinase B (1 U/ml; Sigma) for 4 h and then loaded with IFN-{gamma} (10 ng/ml) for the final 30 min. The cells were then washed and added to responder cells as previously. Chondroitinase ABC inhibited nitrite production to ~20% of control values, whereas chondroitinase B inhibited to ~40% of control values. There was no significant difference between the effects of chondroitinase ABC and chondroitinase B. Chondroitinase AC produced a small but not significant inhibition (Fig. 7Go). These experiments show that IFN-{gamma} binds to chondroitin sulfate B on mouse peritoneal mast cells. In this form, the cytokine is functionally active. Macrophages could also bind and present IFN-{gamma}, but this was via heparan sulfate (Fig. 6Go).



View larger version (28K):
[in this window]
[in a new window]
  		FIGURE 6. Effects of GAG-digesting enzymes on mast cell presentation of IFN-{gamma}. Purified IFN-{gamma}R WT mouse mast cells or peritoneal macrophages (both at 105/ml) were incubated with or without: A, heparinase (1 U/ml) or B, chondroitinase ABC (1 U/ml) for 1 h at 37°C in cDMEM. After washing, they were loaded with IFN-{gamma} at 10 ng/ml, washed again, and added (2 x 105/ml) to peritoneal responder cells (2 x 106/ml) for 24 h, in a final volume of 0.25 ml. Supernatant nitrite levels were determined. Con, control with no IFN-{gamma}. Free IFN-{gamma} was included as a positive control. Hatched bars represent enzyme-treated presenting cells. Results are means ± SEM for four separate experiments, each performed in quadruplicate. *, p < 0.05 by paired Student’s t test, for comparison of cells cultured with or without enzyme.

 


View larger version (15K):
[in this window]
[in a new window]
  		FIGURE 7. Effects of different chondroitinases on mast cell presentation of IFN-{gamma}. Purified IFN-{gamma}R WT mouse mast cells (105/ml) were incubated with chondroitinase ABC (1 U/ml), chondroitinase AC (1 U/ml), chondroitinase B (1 U/ml), or without enzyme (control = 100%) for 4 h, then loaded with IFN-{gamma} (10 ng/ml) for the final 30 min. The cells were then washed and added to responder cells, as previously. The nitrite content of the supernatants was assayed after 24 h. Results are presented as percentage of control (no enzyme) given as means ± SEM for four separate experiments, each performed in quadruplicate. *, p < 0.05 by paired Student’s t test, for comparison with cells cultured without enzyme.

 
Binding of GAGs to IFN-{gamma}

The capacity of various GAGs to inhibit binding of heparin-BSA-biotin to murine IFN-{gamma} was tested by ELISA. Fig. 8Go shows a representative experiment from a series summarized in Table IGo. In all experiments, the positive control inhibitor heparin-BSA reduced binding completely at low concentrations. Heparan sulfate gave significant inhibition in only one of three experiments, whereas chondroitin sulfate B and hyaluronic acid inhibited in all experiments (mean maximum inhibition over all experiments being 75% and 57.5%, respectively). Chondroitin sulfate A and chondroitin sulfate C gave a small but significant inhibition in one of four and one of three experiments, respectively. These assays confirm that chondroitin sulfate B binds to murine IFN-{gamma}.



View larger version (16K):
[in this window]
[in a new window]
  		FIGURE 8. Competitive inhibition ELISA for GAG binding to IFN-{gamma}. Microtiter plates were coated with carrier-free murine rIFN-{gamma}. A range of GAGs (see key) was tested for inhibition of heparin binding to IFN-{gamma} by addition to the plates before heparin-BSA-biotin. Bound heparin-BSA-biotin was detected with extravidin-peroxidase. Results are from a single representative assay. Each point is the mean of three replicate wells, and example SEMs are shown. HS, heparan sulfate; HA, hyaluronic acid; CSA, chondroitin sulfate A; CSB, chondroitin sulfate B; CSC, chondroitin sulfate C.

 

View this table:
[in this window]
[in a new window]
  		Table I. Collated data from inhibition ELISA experimentsa

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
IFN-{gamma} inhibits degranulation of rodent peritoneal mast cells (3, 4, 5, 6), and this activity is through induction of NO synthesis by accessory cells (nonmast cells, largely macrophages) in peritoneal populations (9, 10). NO is a known inhibitor of mast cell and basophil degranulation (30, 31, 32). In the present study, using a novel approach, we confirm that IFN-{gamma} does not target mast cells directly to inhibit IgE-mediated degranulation. In coculture experiments, the cytokine inhibited mast cell serotonin release and induced NO synthesis, only when accessory cells expressed the IFN-{gamma}R. IFN-{gamma} exhibited both of these activities regardless of whether the mast cells were IFN-{gamma}R WT or KO. Therefore, IFN-{gamma} acts at its receptor on accessory cells to induce NO synthesis, and mast cells are suppressed by NO regardless of whether or not they express the IFN-{gamma}R. We were unable to confirm reports that mast cells produce NO (31, 33, 34, 35), at least after incubation with IFN-{gamma}.

Although mast cells did not respond to IFN-{gamma} to produce detectable nitrite, we examined whether IFN-{gamma} could bind to purified mast cells. Surprisingly, we found that biotinylated IFN-{gamma} bound equally to both IFN-{gamma}R WT and KO cells, indicating that binding is independent of IFN-{gamma}R. Additional experiments revealed that the bound IFN-{gamma} retained functional activity, since purified mast cells loaded with IFN-{gamma} were able to stimulate NO synthesis by peritoneal macrophages. This presentation of IFN-{gamma} to NO-producing cells was seen regardless of whether the mast cells expressed the IFN-{gamma}R, but showed an absolute requirement for IFN-{gamma}R expression on the responder cells and was dependent on cell-cell contact. These experiments show that the IFN-{gamma} binds to mast cells via an interaction independent of the IFN-{gamma}R and that, in this state, it can be presented functionally to its receptor on an adjacent cell. Human HMC-1 mast cells were also able to present murine IFN-{gamma} to mouse peritoneal NO-producing cells, showing that this phenomenon is not restricted to rodent mast cells.

We considered proteoglycans as a possible alternative cell surface binding site for IFN-{gamma}. These consist of a protein core with GAG side chains of repeating disaccharide units. Cytokine and growth factor interactions with GAGs have been reported and shown to be important in their functional regulation (36, 37, 38). We therefore investigated whether mast cells might bind IFN-{gamma} through GAGs. Purified mouse peritoneal mast cells exposed to chondroitinase ABC and chondroitinase B had a significantly reduced capacity to present IFN-{gamma}, whereas heparinase and chondroitinase AC had little effect. We found that peritoneal macrophages were also capable of presenting IFN-{gamma} in an autologous manner, but this was heparinase sensitive and chondroitinase ABC resistant. Thus, mouse mast cells appear to use predominantly chondroitin sulfate B (dermatan sulfate), whereas macrophages use heparan sulfate, for functional presentation of IFN-{gamma}. We confirmed by ELISA that IFN-{gamma} had binding activity for dermatan sulfate.

Utilizing endothelial cell layers and immobilized purified GAGs, others have shown that human IFN-{gamma} binds to heparin, heparan sulfate, and chondroitin sulfate, sulfation of the GAGs being essential for in this interaction (12, 13, 14, 15, 16, 39). Binding is thought to be an ionic interaction between positively charged basic amino acids near the C terminus of IFN-{gamma} and the negatively charged sugar residues on GAGs (16). The biological activity of IFN-{gamma} bound to immobilized GAGs or endothelium has been inferred by some and demonstrated by others (12, 14, 15, 16). In the present study, we have demonstrated, for the first time, that dermatan sulfate on the surface of a motile cell type (mast cells) can bind IFN-{gamma} and present it to macrophages, inducing an immunologically important response. Consistent with our findings, it has recently been shown that C-terminal basic peptides of murine IFN-{gamma} interact with heparin, heparan sulfate, and chondroitin sulfate (16). Chondroitin sulfate has also been implicated in the biology of other cytokines and growth factors: chondroitin sulfate B (dermatan sulfate) binds IL-7, IL-12, IL-6, IL-1{alpha} and -{beta}, and human hepatocyte growth factor; promotes fibroblast growth factor-2 function; and regulates heparin affin regulatory peptide activity (37, 40, 41, 42). In addition, chondroitin sulfate present on neutrophils binds PF4, while GM-CSF exists in a biologically active form in association with chondroitin sulfate (43, 44).

The fact that cytokines and growth factors can bind to GAGs has profound functional significance. First of all, GAGs can sequester cytokines and growth factors from the extracellular fluid, providing a mechanism for the spatial and temporal regulation of these mediators. This has been demonstrated for GAGs in the extracellular matrix of bone marrow stroma, model basement membrane (Matrigel), human vascular endothelium, and human arterial smooth muscle cell extracellular matrix (12, 14, 15, 16, 45). These GAG-bound cytokines may be presented either to specific receptors on the same cell in an autocrine manner or to specific receptors on other cells in a juxtacrine manner (46). Second, one GAG may bind multiple molecules of a given cytokine or growth factor, resulting in the concentration of these factors in the local microenvironment and encouraging clustering and the possibility of receptor activation (18, 47). Third, interaction with GAGs can provide protection from proteolytic cleavage, prolonging mediator biological t1/2 (38, 48). Finally, in the case of fibroblast growth factor, interaction with the GAG heparan sulfate is a prerequisite for the delivery of a growth-stimulatory signal (38).

Our results, showing that mast cells can act as a reservoir of stored and functionally active IFN-{gamma}, have implications both for the biological activity of the cytokine and for the role of mast cells in inflammation and immunity, as well as for the understanding of cell-cell interactions during immune responses. Mast cells are motile (49, 50) and are recruited to sites of inflammation (24, 25). The retention of cytokines on their cell surface may result in the spatial and temporal modulation of cytokine action. The aggregation of IFN-{gamma} on mast cell surface dermatan sulfate could change the cytokine microenvironment and extend IFN-{gamma} biological t1/2. In addition, the phenomenon we describe, whereby mast cells can present IFN-{gamma} to NO-producing cells, may lead to mast cell stabilization (9, 10), representing a possible mechanism of negative feedback control of mast cell activation. ELISA results showed that murine IFN-{gamma} could bind dermatan sulfate, but with lower affinity than to heparin, although our coculture experiments illustrate that the off rate from mast cell surface dermatan sulfate is sufficiently slow to allow presentation to occur. It could be envisaged that heparin released from degranulating mast cells would remove IFN-{gamma} from cell surface dermatan sulfate, given the relative affinities of these two GAGs for IFN-{gamma}. Again, this could be a mechanism of regulation of IFN-{gamma} action and NO release.

To our knowledge, this is the first report that motile cells are capable of sequestering a cytokine and presenting it to adjacent cells. It may provide new insight into the role of mast cells in promoting or extending the multiple effects of IFN-{gamma} in inflammatory and immune processes (1, 2). It could be envisaged that cytokines may be sequestered at their site of secretion and carried to other parts of the same anatomical site or to distant sites.


   Footnotes
 
1 This work was funded by the Medical Research Council (U.K.). D.G.F. is supported by the North West Cancer Research Fund (U.K.). Back

2 Address correspondence and reprint requests to Dr. John W. Coleman, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom, L69 3GE. E-mail address: Back

3 Abbreviations used in this paper: KO, knockout; GAG, glycosaminoglycan; WT, wild type. Back

Received for publication August 6, 1999. Accepted for publication October 25, 1999.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Farrar, M. A., R. D. Schreiber. 1993. The molecular cell biology of interferon-{gamma} and its receptor. Annu. Rev. Immunol. 11:571.[Medline]
  2. Billiau, A.. 1996. Interferon-{gamma}: biology and role in pathogenesis. Adv. Immunol. 62:61.[Medline]
  3. Coleman, J. W., M. G. Buckley, M. R. Holliday, A. G. Morris. 1991. Interferon-{gamma} inhibits serotonin release from mouse peritoneal mast cells. Eur. J. Immunol. 21:2559.[Medline]
  4. Holliday, M. R., E. M. S. Banks, R. J. Dearman, I. Kimber, J. W. Coleman. 1994. Interactions of IFN-{gamma} with IL-3 and IL-4 in the regulation of serotonin and arachidonate release from mouse peritoneal mast cells. Immunology 82:70.[Medline]
  5. Swieter, M., W. A. Ghali, C. Rimmer, D. Befus. 1989. Interferon-{alpha}/{beta} inhibits IgE-dependent histamine release from rat peritoneal mast cells. Immunology 66:606.[Medline]
  6. Bissonnette, E. Y., B. Chin, A. D. Befus. 1995. Interferons differentially regulate histamine and TNF-{alpha} in rat intestinal mucosal mast cells. Immunology 86:12.[Medline]
  7. Bissonnette, E. Y., A. D. Befus. 1990. Inhibition of mast cell-mediated cytotoxicity by IFN-{alpha}/{beta} and {gamma}. J. Immunol. 145:3385.[Abstract]
  8. Takagi, M., K. Koike, T. Nakahata. 1990. Antiproliferative effect of IFN-{gamma} on proliferation of mouse connective tissue-type mast cells. J. Immunol. 145:1880.[Abstract]
  9. Eastmond, N. C., E. M. S. Banks, J. W. Coleman. 1997. Nitric oxide inhibits IgE-mediated degranulation of mast cells and is the principal intermediate in IFN-{gamma}-induced suppression of exocytosis. J. Immunol. 159:1444.[Abstract]
  10. DeSchoolmeester, M. L., N. C. Eastmond, R. J. Dearman, I. Kimber, D. A. Basketter, J. W. Coleman. 1999. Reciprocal effects of interleukin-4 and interferon-{gamma} on immunoglobulin E-mediated mast cell degranulation: a role for nitric oxide but not peroxynitrite or cyclic guanosine monophosphate. Immunology 96:138.[Medline]
  11. Coleman, J. W., M. R. Holliday, I. Kimber, K. M. Zsebo, S. J. Galli. 1993. Regulation of mouse peritoneal mast cell secretory function by stem cell factor, IL-3 or IL-4. J. Immunol. 150:556.[Abstract]
  12. Lortat-Jacob, H., H. K. Kleinman, J. A. Grimaud. 1991. High-affinity binding of interferon-{gamma} to a basement membrane complex (Matrigel). J. Clin Invest. 87:878.
  13. Lortat-Jacob, H., J. A. Grimaud. 1991. Interferon-{gamma} binds to heparan sulfate by a cluster of amino acids located in the C-terminal part of the molecule. FEBS Lett. 280:152.[Medline]
  14. Camejo, E. H., B. Rosengren, G. Camejo, P. Sartipy, G. Fager, G. Bondjers. 1995. Interferon {gamma} binds to extracellular matrix chondroitin-sulfate proteoglycans, thus enhancing its cellular response. Arterioscler. Thromb. Vasc. Biol. 15:1456.[Abstract/Free Full Text]
  15. Douglas, M. S., D. A. Rix, J. H. Dark, D. Talbot, J. A. Kirby. 1997. Examination of the mechanism by which heparin antagonizes activation of a model epithelium by interferon-{gamma} (IFN-{gamma}). Clin. Exp. Immunol. 107:578.[Medline]
  16. Fernandez-Botran, R., J. Yan, D. E. Justus. 1999. Binding of interferon {gamma} by glycosaminoglycans: a strategy for localization and/or inhibition of its activity. Cytokine 11:313.[Medline]
  17. Lortat-Jacob, H., J. A. Grimaud. 1992. Binding of interferon-{gamma} to heparan sulfate is restricted to the heparin-like domains and involves carboxylic—but not N-sulfated—groups. Biochim. Biophys. Acta 1117:126.[Medline]
  18. Lortat-Jacob, H., J. E. Turnbull, J. A. Grimaud. 1995. Molecular organization of the interferon-binding domain in heparan sulfate. J. Biochem. 310:497.
  19. Sadir, R., E. Forest, H. Lortat-Jacob. 1998. The heparan sulfate binding sequence of interferon-{gamma} increased the on rate of the interferon-{gamma}-receptor complex formation. J. Biol. Chem. 273:10919.[Abstract/Free Full Text]
  20. Daubener, W., S. Nockemann, M. Gutsche, U. Hadding. 1995. Heparin inhibits the antiparasitic and immune modulatory effects of human recombinant interferon-{gamma}. Eur. J. Immunol. 25:688.[Medline]
  21. Rix, D. A., M. S. Douglas, D. Talbot, J. H. Dark, J. A. Kirby. 1996. Role of glucosaminoglycans in regulation of the immunogenicity of human vascular endothelial cells. Clin. Exp. Immunol. 104:60.[Medline]
  22. Stuehr, D. J., M. A. Marletta. 1987. Synthesis of nitrite and nitrate in murine macrophage cell lines. Cancer Res. 47:5590.[Abstract/Free Full Text]
  23. Ding, A. H., C. F. Nathan, D. J. Stuehr. 1988. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J. Immunol. 141:2407.[Abstract]
  24. Bentley, A. M., Q. Hamid, D. S. Robinson, E. Schotman, Q. Meng, B. Assoufi, A. B. Kay, S. R. Durham. 1996. Prednisolone treatment in asthma: reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-{gamma} cytokine gene expression within the bronchial mucosa. Am. J. Respir. Crit. Care Med. 153:551.[Abstract]
  25. Anderson, D. F., J. D. MacLeod, S. M. Baddeley, A. S. Bacon, J. I. McGill, S. T. Holgate, W. R. Roche. 1997. Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leukocyte infiltration. Clin. Exp. Allergy 27:1060.[Medline]
  26. Huang, S., W. Hendricks, A. Althage, S. Hemmi, H. Bluethmann, R. Kamijo, J. Vilcek, R. M. Zinkernagel, M. Aguet. 1993. Immune response in mice that lack the interferon-{gamma} receptor. Science 259:1742.[Abstract/Free Full Text]
  27. Butterfield, J. H., D. Weiler, G. deWald, G. J. Gleich. 1988. Establishment of an immature mast cell line from a patient with a mast cell leukemia. Leuk. Res. 12:345.[Medline]
  28. Green, L. C., D. A. Wagner, J. Glogowski, P. L. Skipper, J. S. Wishnok, S. R. Tannenbaum. 1982. Analysis of nitrate, nitrite and [15N]-labelled nitrate in biological fluids. Anal. Biochem. 126:131.[Medline]
  29. Lipscombe, R. J., A. M. Nakhoul, C. J. Saunderson, D. R. Coombe. 1998. Interleukin-5 binds to heparin/heparan sulfate: a model for an interaction with extracellular matrix. J. Leukocyte Biol. 63:342.[Abstract]
  30. Salvemini, D., E. Masini, A. Pistelli, P. F. Mannaioni, J. Vane. 1991. Nitric oxide: a regulatory mediator of mast cell reactivity. J. Cardiovasc. Pharmacol. 17:(Suppl. 3):S258.
  31. Masini, E., D. Salvemini, A. Pistelli, P. F. Mannaioni, J. R. Vane. 1991. Rat mast cells synthesize a nitric oxide-like factor which modulates the release of histamine. Agents Actions 33:61.[Medline]
  32. Iikura, M., T. Takaishi, K. Hirai, H. Yamada, T. Koshino, Y. Morita. 1998. Exogenous nitric oxide regulates the degranulation of human basophils and rat peritoneal mast cells. Int. Arch. Allergy Immunol. 115:129.[Medline]
  33. Salvemini, D., E. Masini, E. Anggard, P. F. Mannaioni, J. Vane. 1990. Synthesis of a nitric oxide-like factor from L-arginine by rat serosal mast cells: stimulation of guanylate cyclase and inhibition of platelet aggregation. Biochem. Biophys. Res. Commun. 169:596.[Medline]
  34. Bissonnette, E. Y., C. M. Hogaboam, J. L. Wallace, A. D. Befus. 1991. Potentiation of tumor necrosis factor-{alpha}-mediated cytotoxicity of mast cells by their production of nitric oxide. J. Immunol. 147:3060.[Abstract]
  35. Hogaboam, C. M., A. D. Befus, J. L. Wallace. 1993. Modulation of rat mast cell reactivity by IL-1{beta}: divergent effects on nitric oxide and platelet-activating factor release. J. Immunol. 151:3767.[Abstract]
  36. Ruoslahti, E., Y. Yamaguchi. 1991. Proteoglycans as modulators of growth factor activities. Cell 64:867.[Medline]
  37. Ramsden, L., C. C. Rider. 1992. Selective and differential binding of interleukin (IL)-1{alpha}, IL-1{beta}, IL-2 and IL-6 to glycosaminoglycans. Eur. J. Immunol. 22:3027.[Medline]
  38. Fernig, D. G., J. T. Gallagher. 1994. Fibroblast growth factors: an information network controlling tissue growth, morphogenesis and repair. Prog. Growth Factor Res. 5:353.[Medline]
  39. Yard, B. A., C. P. Lorentz, D. Herr, F. J. Van Der Woude. 1998. Sulfation-dependent down-regulation of interferon-{gamma}-induced major histocompatibility complex class I and II and intercellular adhesion molecule-1 expression on tubular and endothelial cells by glycosaminoglycans. Transplantation 66:1244.[Medline]
  40. Lyon, M., J. A. Deakin, H. Rahmoune., D. G. Fernig, T. Nakamura, J. T. Gallagher. 1998. Hepatocyte growth factor/scatter factor binds with high affinity to dermatan sulfate. J. Biol. Chem. 273:271.[Abstract/Free Full Text]
  41. Penc, S. F., B. Pomahac, T. Winkler, R. A. Dorschner, E. Eriksson, M. Hendron, R. L. Gallo. 1998. Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function. J. Biol. Chem. 273:28116.[Abstract/Free Full Text]
  42. Vancherot, F., J. Delbe, M. Heroult, D. Barritault, D. G. Fernig, J. Courty. 1999. Glycosaminoglycans differently bind HARP and modulate its biological activity. J. Biol. Chem. 274:7741.[Abstract/Free Full Text]
  43. Petersen, F., L. Bock, H.-D. Flad, E. Brandt. 1998. A chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation. J. Immunol. 161:4347.[Abstract/Free Full Text]
  44. Suzu, S., F. Kimura, J. Ota, K. Motoyoshi, T. Itoh, Y. Mishima, M. Yamada, S. Shimamura. 1997. Biological activity of proteoglycan macrophage colony-stimulating factor. J. Immunol. 159:1860.[Abstract]
  45. Gordon, M. Y., G. P. Riley, S. M. Watt, M. F. Greaves. 1988. Compartmentalization of a haematopoietic growth factor (GM-CSF) by glycosaminoglycans in the bone marrow microenvironment. Nature 326:403.
  46. Tanaka, Y., D. H. Adams, H. H. Hubscher, U. Siebenlistand, S. Shaw. 1993. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1{beta}. Nature 361:79.[Medline]
  47. Hoogewerf, A. J., G. S. V. Kuschert, A. E. I. Proudfoot, F. Borlat, I. Clarke-Lewis, C. A. Power, T. N. Wells. 1997. Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 36:13570.[Medline]
  48. Lortat-Jacob, H., F. Baltzer, J.-A. Grimaud. 1996. Heparin decreases the blood clearance of interferon-{gamma} and increases its activity by limiting the processing of its carboxyl-terminal sequence. J. Biochem. 271:16139.
  49. Gruber, B. L., M. J. Marchese, R. Kew. 1995. Angiogenic factors stimulate mast-cell migration. Blood 86:2488.[Abstract/Free Full Text]
  50. Nilsson, G., J. A. Mikovits, D. D. Metcalfe, D. D. Taub. 1999. Mast cell migratory response to interleukin-8 is mediated through interaction with chemokine receptor CXCR2/interleukin-8RB. Blood 93:2791.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
N. Nieuwenhuizen, D. R. Herbert, A. L. Lopata, and F. Brombacher
CD4+ T Cell-Specific Deletion of IL-4 Receptor {alpha} Prevents Ovalbumin-Induced Anaphylaxis by an IFN-{gamma}-Dependent Mechanism
J. Immunol., September 1, 2007; 179(5): 2758 - 2765.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. J. Davis, B. F. Flanagan, A. M. Gilfillan, D. D. Metcalfe, and J. W. Coleman
Nitric Oxide Inhibits IgE-Dependent Cytokine Production and Fos and Jun Activation in Mast Cells
J. Immunol., December 1, 2004; 173(11): 6914 - 6920.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. J. Swindle, D. D. Metcalfe, and J. W. Coleman
Rodent and Human Mast Cells Produce Functionally Significant Intracellular Reactive Oxygen Species but Not Nitric Oxide
J. Biol. Chem., November 19, 2004; 279(47): 48751 - 48759.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. J. Swindle, J. A. Hunt, and J. W. Coleman
A Comparison of Reactive Oxygen Species Generation by Rat Peritoneal Macrophages and Mast Cells Using the Highly Sensitive Real-Time Chemiluminescent Probe Pholasin: Inhibition of Antigen-Induced Mast Cell Degranulation by Macrophage-Derived Hydrogen Peroxide
J. Immunol., November 15, 2002; 169(10): 5866 - 5873.
[Abstract] [Full Text] [PDF]

Home page
 GlycobiologyHome page
J. M. Trowbridge and R. L. Gallo
Dermatan sulfate: new functions from an old glycosaminoglycan
Glycobiology, September 1, 2002; 12(9): 117R - 125R.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
Z. Wu, D. R. Turner, and D. B. G. Oliveira
Antioxidants inhibit mercuric chloride-induced early vasculitis
Int. Immunol., March 1, 2002; 14(3): 267 - 273.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brooks, B.
Right arrow Articles by Coleman, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brooks, B.
Right arrow Articles by Coleman, J. W.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS